Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07219212 · ClinicalTrials.gov registry record · Phase 1

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

A Phase 1 study of Squamous Cell Carcinoma of Head and Neck, sponsored by Johnson & Johnson Enterprise Innovation.

Recruiting
Registry status
Phase 1
Development phase
30
Enrollment target
11
Study locations

NCT07219212: Recruiting Phase 1 study of Squamous Cell Carcinoma of Head and Neck, sponsored by Johnson & Johnson Enterprise Innovation.

NCT07219212 is a Phase 1 study of Squamous Cell Carcinoma of Head and Neck that is actively recruiting participants, run by Johnson & Johnson Enterprise Innovation. The registered enrollment target is 30 participants, below the 170-participant average among 37 other Squamous Cell Carcinoma of Head and Neck trials with a reported enrollment target (82% lower). The trial reports 11 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07219212, a Phase 1 study of Squamous Cell Carcinoma of Head and Neck, is actively recruiting participants, sponsored by Johnson & Johnson Enterprise Innovation.

RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
11
Study locations

Study Summary

This global, open-label, single arm, phase 1b study aims to learn more about whether a treatment called JNJ-90301900 is safe and effective when injected directly into tumors, along with standard chemotherapy and radiation therapy, for participants with head and neck squamous cell cancer (HNSCC; a type of solid tumor that begins in outer tissue layer of the mouth \& throat).

Primary Outcome

An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version (v) 5.0.

Conditions Studied

Squamous Cell Carcinoma of Head and Neck

Interventions

  • DRUG Cisplatin
  • RADIATION Intensity Modulated Radiation Therapy (IMRT)
  • DRUG JNJ-90301900

Study Locations (11)

Other

  • Hopital De La Cavale Blanche - Brest
  • Hopital La Timone - Marseille
  • Centre Henri Becquerel - Rouen
  • Gustave Roussy - Villejuif
  • Aichi Cancer Center - Nagoya
  • Tokyo Medical University Hospital - Tokyo

Florida

  • Mayo Clinic - Jacksonville
  • Moffit Cancer center - Tampa

California

  • City of Hope - Duarte

Georgia

  • Emory University - Atlanta

New York

  • Montefiore Medical Center - The Bronx

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2026-01-26
Est. Completion 2028-07-14
Phase Phase 1
Johnson & Johnson Enterprise Innovation

7 total trials

What NCT07219212 shows while recruiting

NCT07219212 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 170-participant average among 37 other Squamous Cell Carcinoma of Head and Neck trials with a reported enrollment target (82% lower).

The record links to 1 condition, with Squamous Cell Carcinoma of Head and Neck appearing as the primary indexed condition, and to 3 interventions - of which Cisplatin is the first listed.

NCT07219212 lists 11 locations in 5 states (Other, Florida, California).

Frequently Asked Questions

What is clinical trial NCT07219212 about?

NCT07219212 is a clinical study titled "A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma". This global, open-label, single arm, phase 1b study aims to learn more about whether a treatment called JNJ-90301900 is safe and effective when injected directly into tumors, along with standard chemotherapy and radiation therapy, for participants with head and neck squamous cell cancer (HNSCC; a ty...

What is the current status of trial NCT07219212?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2026-01-26. Estimated completion is 2028-07-14.

What conditions does trial NCT07219212 study?

This clinical trial studies the following conditions: Squamous Cell Carcinoma of Head and Neck.

What interventions are being tested in trial NCT07219212?

The interventions under investigation include: Cisplatin (DRUG), Intensity Modulated Radiation Therapy (IMRT) (RADIATION), JNJ-90301900 (DRUG).

Who is sponsoring clinical trial NCT07219212?

This trial is sponsored by Johnson & Johnson Enterprise Innovation, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07219212 being conducted?

This trial has 11 study locations across California, Florida, Georgia, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Squamous Cell Carcinoma of Head and Neck

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07219212's enrollment target sits among peer trials

30 29th of 37 higher than 7 of 37 other Squamous Cell Carcinoma of Head and Neck trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Squamous Cell Carcinoma of Head and Neck trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07219212

Source: ClinicalTrials.gov NCT07219212, the US trial registry maintained by the National Library of Medicine. NCT07219212 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.